In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir Pharmaceuticals Inc.

Division of Otsuka Holdings Co. Ltd.
www.avanir.com

Latest From Avanir Pharmaceuticals Inc.

Otsuka’s Avanir Encouraged By First Peek At Treatment For Alzheimer’s Agitation

Phase III results from Avanir’s candidate for agitation in patients with Alzheimer’s disease offers some hope in a setting for which there is no specific treatment.

Clinical Trials Neurology

Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Deals Financing

Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy

Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.

M & A Biologics

Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion

NDA and BLA submission news from our US FDA Performance Tracker.

Drug Review Regulation
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register